NYSE - Delayed Quote USD

AbbVie Inc. (ABBV)

Time to buy ABBV?

184.02

+2.34

+(1.29%)

At close: May 16 at 4:00:02 PM EDT

183.30

-0.72

(-0.39%)

After hours: May 16 at 7:59:20 PM EDT

Time to buy ABBV?

Don't Fall for These 3 Dividend Stocks: They May Have to Make a Cut.

Here are three dividend-paying stocks that warrant closer examination.

Motley Fool 3 hours ago

PFE

MDT

ABBV
+1.29%
3 Magnificent Stocks That Are Passive Income Machines

Abbott Laboratories is a dividend stock you can buy and (almost) forget about. AbbVie has proved its resilience by becoming stronger after losing patent exclusivity for its blockbuster drug Humira. Johnson & Johnson is a seasoned dividend payer for all seasons.

Motley Fool yesterday

ABBV
+1.29%

JNJ

ABT
Jim Cramer On AbbVie: Makes “Sense To Start a Position in the Stock”

Calling AbbVie Inc. (NYSE:ABBV) one of his “absolute favorites” during the recent episode of Mad Money, Cramer said: “Or how about one of my absolute favorites right here too, AbbVie. Now here’s a drug company with no patent cliff in sight whatsoever. Got tremendous franchises in neurology, oncology, immunology, and medical aesthetics, among others. Because […]

Insider Monkey 2 days ago

ABBV
+1.29%
Some May Be Optimistic About AbbVie's (NYSE:ABBV) Earnings

AbbVie Inc.'s ( NYSE:ABBV ) stock was strong despite it releasing a soft earnings report last week. We think that...

Simply Wall St. 2 days ago

ABBV
+1.29%
Pharma Stock Roundup: BAYRY Q1 Earnings, NVO & GSK's New Deals

Bayer reports first-quarter results. NVO and GSK announce licensing deals with smaller biotechs.

Zacks 2 days ago

ABBV
+1.29%

BAYN.DE

NVO
1 Healthcare Stock to Keep an Eye On and 2 to Ignore

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns - over the past six months, healthcare stocks have collectively shed 6.7%. This performance was disappointing since the S&P 500 held its ground.

StockStory 2 days ago

ABBV
+1.29%

EVH
FDA awards cancer drug approvals to AbbVie and MSD

The FDA has approved MSD’s Welireg for rare adrenal tumours, and AbbVie’s Emrelis for treating c-Met+ lung cancer patients.

Pharmaceutical Technology 2 days ago

ABBV
+1.29%

MRK
AbbVie Secures FDA Nod for New ADC Drug Emrelis in Lung Cancer

Following the approval, ABBV's Emrelis becomes the first FDA-approved therapy for previously treated advanced NSCLC patients with high c-Met protein overexpression.

Zacks 3 days ago

ABBV
+1.29%

ADPT
AbbVie stakes $335M on a startup’s RNAi drugs

ADARx Pharmaceuticals will work with AbbVie to make RNA interference medicines for a variety of disease areas, including neurology, immunology and cancer.

BioPharma Dive 3 days ago

ABBV
+1.29%
AbbVie expands siRNA push with $335m ADARx deal

This marks AbbVie’s second major siRNA deal following its $1.4bn acquisition of Aliada Therapeutics last year.

Pharmaceutical Technology 3 days ago

ABBV
+1.29%
FDA approves Roche’s MET protein expression detecting assay for NSQ-NSCLC

Results from the LUMINOSITY study indicated that those with high c-Met protein expression achieved a 35% ORR.

Medical Device Network 3 days ago

ROG.SW

ABBV
+1.29%
Regeneron Upgraded as AbbVie Catches Policy Heat

Citi sees MFN pricing and PBM threats as manageable for REGN but riskier for ABBV

GuruFocus.com 3 days ago

REGN

ABBV
+1.29%
FDA Fast-Tracks AbbVie's New Lung Cancer Therapy Emrelis For Tough Lung Cancer Cases

The U.S. Food and Drug Administration (FDA) granted accelerated approval to AbbVie Inc.’s (NYSE:ABBV) Emrelis (telisotuzumab vedotin-tllv) for adult patients with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression (OE) who have received a prior systemic therapy. High c-Met protein overexpression is defined as ≥ 50% of tumor cells with strong (3+) staining as determined by an FDA-approved test. This indication is approved based o

Benzinga 3 days ago

ABBV
+1.29%
US FDA approves AbbVie's drug for a type of lung cancer

The treatment, branded as Emrelis, belongs to a class of drugs known as antibody-drug conjugates, which act as "guided-missiles" that target only cancer cells while sparing healthy cells, unlike conventional chemotherapy. Emrelis was approved for a type of non-squamous non-small cell lung cancer (NSCLC), for which patients were previously treated with other drugs but the disease still spread to other parts of the body. These patients also showed an excess of c-Met protein, which is known to trigger tumor development and resistance to certain therapies.

Reuters 4 days ago

ABBV
+1.29%
U.S. FDA Approves EMRELIS™ (telisotuzumab vedotin-tllv) for Adults With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) With High c-Met Protein Overexpression

AbbVie (NYSE: ABBV) today announced that EMRELIS™ (telisotuzumab vedotin-tllv) has been granted accelerated approval by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression (OE) who have received a prior systemic therapy. High c-Met protein overexpression is defined as ≥ 50% of tumor cells with strong (3+) staining as determined by an FDA-approved

PR Newswire 4 days ago

ABBV
+1.29%
AbbVie Inc. (ABBV): Among the Best Dividend Growth Stocks with High Yields

We recently published a list of the 20 Best Dividend Growth Stocks with High Yields. In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against other best dividend growth stocks. Dividend-paying stocks have been gaining popularity among investors due to their long-term advantages. According to Jeremy Zirin, who […]

Insider Monkey 4 days ago

ABBV
+1.29%
Pharma Stock Regeneron Is a Buy, Says Citi. But Be Cautious on AbbVie, Merck.

Uncertainty around pharma tariffs on and pricing policies under the Trump has much of the sector guessing what will happen next.

Barrons.com 4 days ago

ABBV
+1.29%

REGN
AbbVie, Merck cut to Neutral at Citi

Investing.com -- Citi downgraded both AbbVie (NYSE:ABBV) and Merck (NSE:PROR) to Neutral in separate notes Wednesday, citing long-term growth concerns and late-stage pipeline limitations as headwinds for the pharmaceutical giants.

Investing.com 4 days ago

ABBV
+1.29%
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know

AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Zacks 4 days ago

ABBV
+1.29%
AbbVie and ADARx Pharmaceuticals Announce Collaboration and License Option Agreement to Develop Next-Generation siRNA Therapies Across Multiple Therapeutic Areas

AbbVie (NYSE: ABBV) and ADARx Pharmaceuticals, a late clinical-stage biotechnology company developing next-generation RNA therapeutics, today announced a collaboration and license option agreement to develop small interfering RNA (siRNA) therapeutics across multiple disease areas, including neuroscience, immunology and oncology.

PR Newswire 4 days ago

ABBV
+1.29%

Performance Overview

Return	ABBV	S&P 500 (^GSPC)
YTD	+5.50%	+1.30%
1-Year	+16.04%	+12.48%
3-Year	+32.59%	+48.66%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

AbbVie Inc. (ABBV)

Don't Fall for These 3 Dividend Stocks: They May Have to Make a Cut.

3 Magnificent Stocks That Are Passive Income Machines

Jim Cramer On AbbVie: Makes “Sense To Start a Position in the Stock”

Some May Be Optimistic About AbbVie's (NYSE:ABBV) Earnings

Pharma Stock Roundup: BAYRY Q1 Earnings, NVO & GSK's New Deals

1 Healthcare Stock to Keep an Eye On and 2 to Ignore

FDA awards cancer drug approvals to AbbVie and MSD

AbbVie Secures FDA Nod for New ADC Drug Emrelis in Lung Cancer

AbbVie stakes $335M on a startup’s RNAi drugs

AbbVie expands siRNA push with $335m ADARx deal

FDA approves Roche’s MET protein expression detecting assay for NSQ-NSCLC

Regeneron Upgraded as AbbVie Catches Policy Heat

FDA Fast-Tracks AbbVie's New Lung Cancer Therapy Emrelis For Tough Lung Cancer Cases

US FDA approves AbbVie's drug for a type of lung cancer

U.S. FDA Approves EMRELIS™ (telisotuzumab vedotin-tllv) for Adults With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) With High c-Met Protein Overexpression

AbbVie Inc. (ABBV): Among the Best Dividend Growth Stocks with High Yields

Pharma Stock Regeneron Is a Buy, Says Citi. But Be Cautious on AbbVie, Merck.

AbbVie, Merck cut to Neutral at Citi

AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know

AbbVie and ADARx Pharmaceuticals Announce Collaboration and License Option Agreement to Develop Next-Generation siRNA Therapies Across Multiple Therapeutic Areas

Performance Overview